{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for haloperidol root_notes_note in Note (approximate match)
Status:
US Previously Marketed
Source:
AKINETON by ABBVIE
(1959)
Source URL:
First approved in 1959
Source:
AKINETON by ABBVIE
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Conditions:
Biperiden, sold under the brandname Akineton was used as an adjunct in the therapy of all forms of parkinsonism (postencephalitic, arteriosclerotic and idiopathic). Was also useful in the control of extrapyramidal disorders due to central nervous system drugs such as phenothiazines and other groups of psychotropics. Biperiden is a weak peripheral anticholinergic agent. It has, therefore, some antisecretory, antispasmodic and mydriatic effects. In addition, biperiden possesses nicotinolytic activity. Parkinsonism is thought to result from an imbalance between the excitatory (cholinergic) and inhibitory (dopaminergic) systems in the corpus striatum. The mechanism of action of centrally active anticholinergic drugs such as biperiden is considered to relate to competitive antagonism of acetylcholine at cholinergic receptors in the corpus striatum, which then restores the balance. Atropine-like side effects such as dry mouth; blurred vision; drowsiness; euphoria or disorientation; urinary retention; postural hypotension; constipation; agitation; disturbed behavior may been seen. Only limited pharmacokinetic studies of biperiden in humans are available.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2023)
Source URL:
First approved in 2023
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
Source:
Chi-Myst ResolveTopical by Prescription Care LLC
(2016)
Source URL:
First approved in 2016
Source:
Chi-Myst ResolveTopical by Prescription Care LLC
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
First approved in 2015
Source:
B Vial by Prodibio SAS
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Ethacridine (Rivanol) is an acridine derivative indicated for the treatment of bacterial infections. In many countries the drug was in clinical practice for the second trimester termination of pregnancy.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Bamipine (trade name Soventol) is a sedating antihistamine with pronounced sedative effects. Bamipine is a pharmaceutical drug acting as an H1 antihistamine with anticholinergic properties. It is used as an antipruritic ointment. Bamipine hydrochloride has been given by mouth. Bamipine, bamipine lactate, and bamipine salicylate have all been applied topically.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Zinc lactate is used to eliminate halitosis. Halitosis (commonly
known as bad breath) is a condition affecting many people and one of the most usual reasons why people go look for a dentist’s advice. The main
origin of halitosis is related to the volatile sulphur compounds (VSC) produced by the different bacterial colonies found on the tongue and in the
gingival crevices. Zinc lactate is a very effective solution to neutralize the VSC and an excellent ingredient for mouthwashes and toothpastes.
Status:
Other
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 334
(2018)
Source URL:
First approved in 2018
Source:
21 CFR 334
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M032
(2017)
Source URL:
First approved in 2017
Source:
BEST FACE FORWARD by ASPIRE BRANDS INC
Source URL:
Class:
MIXTURE